We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+9.96%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+632.23%
AUM
$51.2B
AUM Growth
+$4.14B
(+8.8%)
Cap. Flow
+$445M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
19.89%
Holding
3,234
New
648
Increased
710
Reduced
838
Closed
835
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.99B |
| 2 |
Microsoft
MSFT
|
+$522M |
| 3 |
Advanced Micro Devices
AMD
|
+$511M |
| 4 |
Amazon
AMZN
|
+$318M |
| 5 |
Apple
AAPL
|
+$317M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$402M |
| 2 |
McDonald's
MCD
|
+$375M |
| 3 |
Visa
V
|
+$366M |
| 4 |
Meta Platforms (Facebook)
META
|
+$319M |
| 5 |
Adobe
ADBE
|
+$272M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.58% |
| 2 | Healthcare | 17.11% |
| 3 | Consumer Discretionary | 13.31% |
| 4 | Financials | 8% |
| 5 | Industrials | 6.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2301
Anavex Life Sciences
AVXL
$319M
| $91.9K | ﹤0.01% |
11,299
-36,401
| -76% | -$312K |
|
2302
Oportun Financial
OPRT
$354M
| $88.4K | ﹤0.01% |
+14,800
| New | +$72.6K |
|
2303
Rockwell Medical
RMTI
$28.1M
| $87.9K | ﹤0.01% |
+1,611
| New | +$49.5K |
|
2304
Torrid Holdings
CURV
$244M
| $87.8K | ﹤0.01% |
+31,244
| New | +$99.8K |
|
|
BCOV
2305
DELISTED
Brightcove, Inc.
BCOV
| $87.1K | ﹤0.01% |
21,713
-80,679
| -79% | -$326K |
|
2306
Kopin
KOPN
$965M
| $85.6K | ﹤0.01% |
39,825
-46,478
| -54% | -$69.7K |
|
2307
Entravision Communication
EVC
$807M
| $85.6K | ﹤0.01% |
+19,500
| New | +$99.3K |
|
2308
Neonode
NEON
$15.9M
| $85.1K | ﹤0.01% |
10,527
| – | – |
|
2309
Energy Vault
NRGV
$652M
| $82.2K | ﹤0.01% |
30,120
-231,270
| -88% | -$487K |
|
|
PRPH
2310
DELISTED
ProPhase Labs
PRPH
| $81.7K | ﹤0.01% |
1,126
-4,082
| -78% | -$332K |
|
|
TRVG
2311
trivago
TRVG
$376M
| $81.7K | ﹤0.01% |
+12,379
| New | +$79.3K |
|
2312
NatWest
NWG
$75.9B
| $81.4K | ﹤0.01% |
13,293
-72,138
| -84% | -$474K |
|
2313
Altisource Portfolio Solutions
ASPS
$65.1M
| $80.1K | ﹤0.01% |
1,757
-731
| -29% | -$27.1K |
|
|
VLD
2314
DELISTED
Velo3D, Inc.
VLD
| $79.1K | ﹤0.01% |
1,046
-1,677
| -62% | -$117K |
|
|
DESP
2315
DELISTED
Despegar.com
DESP
| $78.3K | ﹤0.01% |
+11,100
| New | +$68.2K |
|
2316
Ocular Therapeutix
OCUL
$2.12B
| $78.2K | ﹤0.01% |
+15,149
| New | +$90.1K |
|
|
TUYA
2317
Tuya Inc
TUYA
$1.11B
| $77.8K | ﹤0.01% |
41,162
| – | – |
|
2318
INNOVATE Corp
VATE
$104M
| $76K | ﹤0.01% |
4,341
-5,869
| -57% | -$126K |
|
|
AEVA
2319
Aeva Technologies
AEVA
$1.71B
| $75.7K | ﹤0.01% |
12,108
+2,824
| +30% | +$16.1K |
|
2320
ThredUp
TDUP
$407M
| $72.8K | ﹤0.01% |
29,846
-140,555
| -82% | -$368K |
|
|
NFGC
2321
New Found Gold
NFGC
$645M
| $72.6K | ﹤0.01% |
14,660
-54,440
| -79% | -$260K |
|
2322
DHI Group
DHX
$160M
| $72.5K | ﹤0.01% |
18,935
-170,666
| -90% | -$633K |
|
|
GMDA
2323
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $72.5K | ﹤0.01% |
+37,561
| New | +$64.6K |
|
2324
Amprius Technologies
AMPX
$1.73B
| $72.4K | ﹤0.01% |
+10,088
| New | +$86.6K |
|
|
PSTX
2325
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $71.7K | ﹤0.01% |
40,760
-407,985
| -91% | -$1.04M |
|
Similar funds
Marshall Wace's Q2 2023 Portfolio in Review
As of Q2 2023, Marshall Wace held 3,234 positions worth $51.2B, up 8.8% from $47.1B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Marshall Wace's Q2 2023 filing shows 648 new, 710 increased, 838 reduced and 835 closed positions. Its largest new stake was iShares Core S&P 500 ETF: 4,713,944 shares worth $2.1B. The largest sale was Gilead Sciences, an estimated $402M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Marshall Wace's largest Q2 2023 buy was iShares Core S&P 500 ETF: 4,713,944 shares worth $2.1B.
- Marshall Wace added most to Microsoft in Q2 2023, an estimated $522M increase.
- Marshall Wace's biggest Q2 2023 reduction was Gilead Sciences, cutting an estimated $402M.
- Marshall Wace fully exited Cloudflare in Q2 2023, selling an estimated $136M.
- Marshall Wace's ten largest holdings make up 20% of its $51.2B portfolio in Q2 2023.
- Marshall Wace opened 648 new positions and closed 835 in Q2 2023.
- Marshall Wace's portfolio value rose 8.8% quarter-over-quarter to $51.2B.
Based on Marshall Wace's 13F filing for Q2 2023, filed 14 Aug 2023.